Literature DB >> 30169981

Advanced fabrication approaches to controlled delivery systems for epilepsy treatment.

Gilles Sebastiaan van Tienderen1,2, Marius Berthel1,3, Zhilian Yue1, Mark Cook1,4,5, Xiao Liu1, Stephen Beirne1, Gordon G Wallace1.   

Abstract

INTRODUCTION: Epilepsy is a chronic brain disease characterized by unprovoked seizures, which can have severe consequences including loss of awareness and death. Currently, 30% of epileptic patients do not receive adequate seizure alleviation from oral routes of medication. Over the last decade, local drug delivery to the focal area of the brain where the seizure originates has emerged as a potential alternative and may be achieved through the fabrication of drug-loaded polymeric implants for controlled on-site delivery. AREAS COVERED: This review presents an overview of the latest advanced fabrication techniques for controlled drug delivery systems for refractory epilepsy treatment. Recent advances in the different techniques are highlighted and the limitations of the respective techniques are discussed. EXPERT OPINION: Advances in biofabrication technologies are expected to enable a new paradigm of local drug delivery systems through offering high versatility in controlling drug release profiles, personalized customization and multi-drug incorporation. Tackling some of the current issues with advanced fabrication methods, including adhering to GMP-standards and industrial scale-up, together with innovative solutions for complex designs will see to the maturation of these techniques and result in increased clinical research into implant-based epilepsy treatment. ABBREVIATIONS: GMP: Good manufacturing process; DDS(s): Drug delivery system(s); 3D: Three-dimensional; AEDs: Anti-epileptic drugs; BBB: Blood brain barrier; PLA: Polylactic acid; PLGA: Poly(lactic-co-glycolic acid); PCL: poly(ɛ-caprolactone); ESE: Emulsification solvent evaporation; O/W: Oil-in-water; W/O/W: Water-in-oil-in-water; DZP: Diazepam; PHT: Phenytoin; PHBV: Poly(hydroxybutyrate-hydroxyvalerate); PEG: Polyethylene glycol; SWD: Spike-and-wave discharges; CAD: Computer aided design; FDM: Fused deposition modeling; ABS: Acrylonitrile butadiene styren; eEVA: Ethylene-vinyl acetate; GelMA: Gelatin methacrylate; PVA: Poly-vinyl alcohol; PDMS: Polydimethylsiloxane; SLA: Stereolithography; SLS: Selective laser sintering.

Entities:  

Keywords:  Advanced fabrication; controlled drug delivery systems; epilepsy; implant drug delivery; three-dimensional printing

Mesh:

Substances:

Year:  2018        PMID: 30169981     DOI: 10.1080/17425247.2018.1517745

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  5 in total

1.  Rat Calvarial Bone Regeneration by 3D-Printed β-Tricalcium Phosphate Incorporating MicroRNA-200c.

Authors:  Matthew T Remy; Adil Akkouch; Li He; Steven Eliason; Mason E Sweat; Tadkamol Krongbaramee; Fan Fei; Fang Qian; Brad A Amendt; Xuan Song; Liu Hong
Journal:  ACS Biomater Sci Eng       Date:  2021-08-26

2.  Controlled Release of Naringin in GelMA-Incorporated Rutile Nanorod Films to Regulate Osteogenic Differentiation of Mesenchymal Stem Cells.

Authors:  Yangjie Shao; Dongqi You; Yiting Lou; Jianhua Li; Binbin Ying; Kui Cheng; Wenjian Weng; Huiming Wang; Mengfei Yu; Lingqing Dong
Journal:  ACS Omega       Date:  2019-11-06

Review 3.  Bypassing the Blood-Brain Barrier: Direct Intracranial Drug Delivery in Epilepsies.

Authors:  Manuela Gernert; Malte Feja
Journal:  Pharmaceutics       Date:  2020-11-24       Impact factor: 6.321

Review 4.  Gelatin Methacryloyl Hydrogels for Musculoskeletal Tissue Regeneration.

Authors:  Yang-Hee Kim; Jonathan I Dawson; Richard O C Oreffo; Yasuhiko Tabata; Dhiraj Kumar; Conrado Aparicio; Isha Mutreja
Journal:  Bioengineering (Basel)       Date:  2022-07-21

Review 5.  Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?

Authors:  Wolfgang Löscher; Alon Friedman
Journal:  Int J Mol Sci       Date:  2020-01-16       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.